Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | XON7 |
| Synonyms | |
| Therapy Description |
XON7 is a glyco-humanized polyclonal antibody that targets tumor cells and induces complement dependent cytotoxicity and apoptosis, potentially resulting in tumor growth inhibition (J Clin Oncol 41, 16_suppl (June 01, 2023)). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| XON7 | XON7 is a glyco-humanized polyclonal antibody that targets tumor cells and induces complement dependent cytotoxicity and apoptosis, potentially resulting in tumor growth inhibition (J Clin Oncol 41, 16_suppl (June 01, 2023)). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06154291 | Phase Ib/II | XON7 | FIH XON7 in Advanced/Metastatic Solid Tumors (FIPO23) | Recruiting | FRA | BEL | 0 |